文章核心观点 - 布里斯托尔-迈尔斯-斯奎布公司(BMY)第二季度每股收益2.07美元,超出了Zacks共识预期的1.64美元 [1] - 公司营收为122亿美元,超出了Zacks共识预期5.93% [3] - 公司过去4个季度连续4次超出共识每股收益预期 [2] 行业和公司分析 行业概况 - 公司所属的医疗-生物医药和遗传学行业目前在250多个Zacks行业中排名前33% [10] - 排名前50%的Zacks行业相比排名后50%的行业业绩要好2倍以上 [10] 公司表现 - 公司今年以来股价下跌11.8%,而标普500指数上涨13.2% [4] - 公司当前地位为Zacks排名3(持有),预计未来表现将与市场持平 [8] - 分析师对公司未来几个季度和本财年的每股收益预期有所变动 [6][9]

财务表现 - 第二季度营收为122亿美元，同比增长9%（调整外汇影响后为11%）[3] - 2024年第二季度净产品销售额为119.25亿美元，较2023年同期增长9.3%[61] - 2024年上半年，Bristol-Myers Squibb公司的总收入为24066亿美元，同比增长10%[73] - 2024年第二季度每股基本收益为0.83美元，较2023年同期下降16.2%[65] - 2024年上半年，Opdivo的收入为4465亿美元，同比增长3%[73] - 2024年上半年，Reblozyl的收入为779亿美元，同比增长92%[73] - 2024年上半年，Eliquis的收入为7136亿美元，同比增长11%[73] - 2024年上半年，Legacy Portfolio的总收入为13678亿美元，同比增长6%[73] - 2024年，国际收入受外汇影响的百分比[75] - 2024年第二季度，总收入增长率为7%[82] - 营业利润率为33.7%[82] - 2024年上半年，总收入增长率为7%[84] - 营业利润率为33.2%[84] - 公司在2024年第二季度的净债务为453.79亿美元，较上一季度增加了18.25亿美元[103] - 公司在2024年第二季度的研发支出为55.94亿美元，较上一季度减少了9.53亿美元[95] - 公司在2024年第二季度的净利润为41.92亿美元，较上一季度增加了15.13亿美元[95] 产品批准 - FDA批准Breyanzi用于扩展到滤泡性淋巴瘤和外套膜细胞淋巴瘤[27] - FDA批准Krazati用于治疗KRAS突变的结直肠癌[28] - FDA批准了Augtyro™用于治疗12岁及以上患有神经营养性酪氨酸受体激酶(NTRK)基因融合的实体瘤患者[29] - Opdivo在欧盟获得批准，与顺铂和吉西他滨联合用于治疗泌尿上皮癌[29] - Opdivo加Yervoy获得EMA对第一线治疗微卫星不稳定性高或错配修复缺陷性转移性结直肠癌的类型II变体申请验证[29] - FDA接受了nivolumab皮下制剂的生物制品许可申请，截止日期为2024年12月29日[29] - Opdivo加Yervoy在治疗不可切除的HCC患者方面显著改善总生存率[29] - Krazati在治疗KRAS突变非小细胞肺癌方面显示出显著的临床意义[29] - FDA批准了Breyanzi用于治疗成人复发或难治性辅助细胞淋巴瘤[31] - FDA加速批准了Breyanzi用于治疗复发或难治性滤泡性淋巴瘤[31] - cendakimab在EoE患者中的III期试验达到了显著的临床效果[32] - Sotyktu®在中度至重度斑块状银屑病患者中表现出持续的临床反应[32] 产品销售 - 成长组合营收为56亿美元，同比增长18%（调整外汇影响后为21%）[4] - 成长组合全球营收增长18%，主要受Opdivo、Reblozyl等产品需求增加[22] - 传统组合全球营收增长2%，主要受Eliquis和Pomalyst需求增加[24] - 成长组合产品在2024年上半年实现收入10388亿美元，同比增长15%[73] - 成长组合中，Opdivo的收入增长率为18%，Reblozyl的收入增长率为41%[76] - 2024年上半年，Opdivo的收入增长率为16%，Reblozyl的收入增长率为82%[79] 市场表现 - 美国市场营收增长13%，主要受益于成长和传统组合[11] - 国际市场营收下降1%，主要受外汇负面影响和Revlimid影响[11]

文章核心观点 - 布里斯托尔-迈尔斯-斯奎布公司(以下简称"公司")第二季度业绩超预期,公司上调了全年收入和利润指引 [2][3][4] - 公司正在采取成本削减措施,计划到2025年削减15亿美元成本,并将资金投入到关键药品和研发项目中 [5] - 公司主要收入增长来自于其重要药品Eliquis和Opdivo,但也面临着Revlimid等重要药品专利到期的压力 [8][9][10] 公司业绩 - 公司第二季度营收为122亿美元,同比增长9% [6] - 公司第二季度调整后每股收益为2.07美元,超出市场预期 [6] - 公司上调了2024年调整后每股收益指引,从之前的0.40-0.70美元上调至0.60-0.90美元 [4] 收入驱动因素 - Eliquis血液制剂和Opdivo肿瘤药物销售强劲,带动了公司整体收入增长 [8] - 尽管面临仿制药竞争,但Revlimid血液肿瘤药物销售仍超出分析师预期 [9] 未来挑战 - 公司面临Eliquis、Opdivo等重要药品专利到期的收入压力 [9] - 2026年Eliquis在Medicare患者群体的价格谈判将对其销售产生影响 [10]

Bristol Myers Squibb (BMY) announced that the European Medicines Agency (EMA) has validated its type II variation application for immunotherapy drug Opdivo (nivolumab), in combination with Yervoy (ipilimumab).The application seeks approval of Opdivo plus Yervoy as a potential first-line treatment option for adult patients with unresectable or advanced hepatocellular carcinoma (HCC) who have not received any prior systemic therapy.The application is based on results from the late-stage CheckMate -9DW trial, ...

Defensive stocks are stealing the spotlight again following Fed Chair Jerome Powell’s recent comments.In his address at the Economic Club of Washington D.C., Powell talked about the precarious state of the economy. His remarks emphasized the stickiness in inflation, policy uncertainties, and large deficits amid full employment. Hence, given the breadth of variables impacting the economy, it seems like a tough road ahead for those expecting quick monetary easing. The Federal Reserve plans to approach policy ...

The market expects Bristol Myers Squibb (BMY) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be rel ...

The latest trading session saw Bristol Myers Squibb (BMY) ending at $42.39, denoting a -1.76% adjustment from its last day's close. This change lagged the S&P 500's 0.78% loss on the day. Elsewhere, the Dow saw a downswing of 1.29%, while the tech-heavy Nasdaq depreciated by 0.7%.Prior to today's trading, shares of the biopharmaceutical company had gained 5.73% over the past month. This has outpaced the Medical sector's gain of 2.23% and the S&P 500's gain of 2.14% in that time.Market participants will be c ...

hapabapa When looking at different pharmaceutical stocks, we see several companies rather struggling in the last few years. Of course, not every company and stock is struggling - Novo Nordisk (NVO) and Eli Lilly (LLY) for example, continue to rush from all-time high to all-time high. But stocks like Pfizer (PFE) and Bristol-Myers Squibb (NYSE:BMY) are declining lower and lower in the last few quarters. And the S&P Pharmaceutical ETF barely moved in the last five years while the S&P 500 (SPY) rushed from all ...

Andre Banyai/iStock via Getty Images BMY's Investment Thesis Is Closely Tied To The Potential Reversal In Its Patent Cliff & Rich Dividend Yields We previously covered Bristol-Myers Squibb Company (NYSE:BMY) in April 2024, discussing why we had finally rated the stock as a Buy as it offered a relatively rich forward dividend yield of 5.02% at the time of writing with the Seeking Alpha Quant still grading its payout safety as B-. Combined with its promising profitability metrics and its overly discounted ...

According to NextEarningsDate.com, the Bristol-Myers Squibb next earnings date is projected to be 7/26 before market open, with earnings estimates of $1.53/share on $10.56 Billion of revenue.Looking back, the recent Bristol-Myers Squibb earnings history looks like this:BMYtickertechThe company has the following long-term earnings per share chart:BMYtickertechAnd with impressive revenue growth:BMYtickertechBut earnings reports can often uniquely bring abrupt volatility to a stock, in either direction, as inv ...